
Paolo Tarantino/X
Feb 28, 2025, 08:09
Paolo Tarantino: The SERENA6 phase 3 trial is positive
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“The SERENA6 phase 3 trial is positive: a switch to camizestrant + CDK4/6i (vs continuation of AI + CDK4/6i) upon emergence of ESR1 mutations led to a significant improvement in PFS.
PFS2 and OS, which will be key to interpret the results, remain immature.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 23:21
Mar 30, 2025, 18:52
Mar 30, 2025, 18:31